Anna Jetske Baron,1– 3 Bertine MJ Flokstra-de Blok,1,2,4 Huib AM Kerstjens,2,3 Gineke Koopmans-Klein,5 David B Price,6,7 Andrea A Sellink,8 Ioanna Tsiligianni,9 Janwillem WH Kocks1,2,6 1General Practitioners Research Institute, Groningen, the Netherlands; 2University of Groningen, University Medical Center Groningen, GRIAC Research Institute, Groningen, the Netherlands; 3University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases and Tuberculosis, Groningen, the Netherlands; 4University of Groningen, University Medical Center Groningen, Beatrix Children’s Hospital, Department of Pediatric Pulmonology and Pediatric Allergology, Groningen, the Netherlands; 5Mundipharma Pharmaceuticals, Leusden, the Netherlands; 6Observational and Pragmatic Research Institute, Singapore; 7Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK; 8AstraZeneca, Den Haag, the Netherlands; 9Health Planning Unit, Department of Social Medicine, University of Crete, Crete, GreeceCorrespondence: Bertine MJ Flokstra-de Blok Prof. E.D. Wiersmastraat 5, Groningen, 9713 GH, the NetherlandsTel +31 50 2113898Email bertine@gpri.nlPurpose: Many patients with asthma still have insufficient disease control, despite the availability of effective treatment options. A substantial proportion of patients appear to rely more on short-acting beta2-agonist (SABA) rather than on anti-inflammatory maintenance treatment. The aim of this study was to describe differences in indicators of asthma symptoms and exacerbations among patients using more or less SABA than the guideline-recommended threshold of < 3 times/week.Patients and Methods: Data from Dutch respondents in the European REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey were used in this post hoc analysis. The survey included asthma patients aged 18– 50 years with at least two prescriptions for their asthma in the past two years. SABA use was categorized into two groups: < 3 (low-SABA ...